GW Pharma clinical trial data on Epidiolex efficacy and safety

GW Pharma clinical trial data on Epidiolex efficacy and safety The passage contains only publicly available trial results for a pharmaceutical product, with no mention of influential actors, financial flows, or misconduct. It offers no actionable investigative leads. Key insights: Epidiolex (CBD) reduced drop seizures by 42% vs 17% for placebo in a Phase III trial.; Dose‑response observed: 20 mg/kg showed greater reduction than 10 mg/kg.; Adverse events were more common in the treatment arms but generally manageable.